Buspirone, Stress, and Attentional Bias to Marijuana Cues

• Sponsor: The University of Texas Health Science Center, Houston (Other)
• Overall Status: Completed
• CT.gov ID: NCT02132832
• Collaborator: National Institute on Drug Abuse (NIDA) (NIH)
• Enrollment: 45
• Location: 1
• Arms: 2
• Duration (Months): 33
• Patients Per Site Per Month: 1.4

Study Details

Study Description

Brief Summary

This project has two primary goals. The first goal is to further scientific understanding about marijuana abuse by examining two recognized factors in marijuana use and relapse: (1) stress/anxiety and (2) atypical reactivity to marijuana-related stimuli (e.g., attentional bias). The second goal is to attenuate the influence of stress/anxiety and attentional bias to marijuana stimuli via administration of buspirone.

Buspirone is uniquely suited to this project because it has effects on neurotransmitter systems known to modulate both stress/anxiety and attentional bias.

Condition or Disease	Intervention/Treatment	Phase
Cannabis Use Disorder	Drug: Buspirone; Drug: Placebo	Phase 2

Detailed Description

For nearly 40 years marijuana has remained the most widely used illicit drug in the US, with more than 50% of first-time users < age 18. Marijuana accounts for ≈ 60% of illicit substance use disorders (SUD) in the US, bearing by percent the largest US public health burden among illicit substances. Across preclinical, human laboratory, and clinical interview data, there is compelling evidence that the phenomenon of cue reactivity is related to drug seeking and relapse. Attentional bias is a measurable component of cue reactivity, and can be operationally defined as differential attention (e.g., reaction time difference) towards drug-related stimuli vs. neutral stimuli. This phenomenon has been demonstrated in SUD populations across many classes of abused drugs, including alcohol, nicotine, stimulants, opiates, and - importantly - marijuana. Cue reactivity and attentional bias are exacerbated by acute and chronic stress and anxiety. Notably, stress is a well-documented predictor of marijuana abuse and marijuana relapse. Therapeutic interventions that attenuate attentional bias to marijuana cues are a potentially important component in the treatment of marijuana SUD. Due to the well-documented association with stress, an intervention that simultaneously addresses both stress and attentional bias could be uniquely efficacious. Currently, few pharmacotherapies exist for marijuana SUD, and none are presently known to address attentional bias to marijuana cues. This application will explore the potential of the anxiolytic buspirone to modify attentional bias and stress. Buspirone is a unique compound marked by modulation of both serotonin (5-HT1A) and dopamine D3 receptors. Importantly, the 5-HT1A receptor is known to play a key role in stress related anxiety, and preclinical work indicates that D3 antagonists significantly decrease cue reactivity to a number of abused drugs. This combination of effects suggests buspirone may be advantageous in targeting both stress and attentional bias as factors that contribute to problem marijuana use.

Accordingly, this project seeks to examine the effects of chronic buspirone administration on attentional bias and stress/anxiety in marijuana SUD. Using laboratory-based methodologies sensitive to attentional bias towards marijuana cues and well validated measures of stress and anxiety, we will examine if buspirone's unique mechanism of action will (a) produce an attenuation of attentional bias to marijuana cues, and (b) be most pronounced under conditions in which attentional bias is related to high levels of stress and anxiety.

Study Design

• Study Type: Interventional
• Actual Enrollment: 45 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Investigator, Outcomes Assessor)
• Primary Purpose: Basic Science
• Official Title: Buspirone, Stress, and Attentional Bias to Marijuana Cues
• Study Start Date: Jun 1, 2013
• Actual Primary Completion Date: Mar 1, 2016
• Actual Study Completion Date: Mar 1, 2016

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Buspirone Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.	Drug: Buspirone; Buspirone is an anxiolytic compound marked by modulation of both 5-HT1A and D3 receptors. Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
Placebo Comparator: Placebo Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.	Drug: Placebo; Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.; Other Names: corn starch

Outcome Measures

Primary Outcome Measures

1. Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements [week 1]

   Eye movements are analyzed using a MiraMetrix S2 Eyetracker. This outcome measure reports a ratio: [(number of anti-saccade errors with marijuana-related images) divided by (total number of anti-saccade errors with marijuana-related images or neutral images)]. Anti-saccade errors are when the subject fails to inhibit fixation onto the image.

2. Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements [week 2]

   Eye movements are analyzed using a MiraMetrix S2 Eyetracker. This outcome measure reports a ratio: [(number of anti-saccade errors with marijuana-related images) divided by (total number of anti-saccade errors with marijuana-related images or neutral images)]. Anti-saccade errors are when the subject fails to inhibit fixation onto the image.

3. Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements [week 3]

   Eye movements are analyzed using a MiraMetrix S2 Eyetracker. This outcome measure reports a ratio: [(number of anti-saccade errors with marijuana-related images) divided by (total number of anti-saccade errors with marijuana-related images or neutral images)]. Anti-saccade errors are when the subject fails to inhibit fixation onto the image.

4. Stress as Assessed by the Perceived Stress Scale [week 1]

   The Perceived Stress Scale is a 10 item scale that was developed to measure the degree to which individuals appraise their life as stressful and has been widely used in health studies. The scale has a 5-point Likert response format. The total score is calculated by summing responses. The questions are general in nature and relatively content free with regard to specific population groups. The range of scores is 0-40, with 40 indicating the most stress.

5. Stress as Assessed by the Perceived Stress Scale [week 2]

   The Perceived Stress Scale is a 10 item scale that was developed to measure the degree to which individuals appraise their life as stressful and has been widely used in health studies. The scale has a 5-point Likert response format. The total score is calculated by summing responses. The questions are general in nature and relatively content free with regard to specific population groups. The range of scores is 0-40, with 40 indicating the most stress.

6. Stress as Assessed by the Perceived Stress Scale [week 3]

   The Perceived Stress Scale is a 10 item scale that was developed to measure the degree to which individuals appraise their life as stressful and has been widely used in health studies. The scale has a 5-point Likert response format. The total score is calculated by summing responses. The questions are general in nature and relatively content free with regard to specific population groups. The range of scores is 0-40, with 40 indicating the most stress.

7. Anxiety as Assessed by the Zung Self-Rated Anxiety Scale [week 1]

   The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80: 20-44 Normal Range 45-59 Mild to Moderate Anxiety Levels 60-74 Marked to Severe Anxiety Levels 75-80 Extreme Anxiety Levels

8. Anxiety as Assessed by the Zung Self-Rated Anxiety Scale [week 2]

   The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80: 20-44 Normal Range 45-59 Mild to Moderate Anxiety Levels 60-74 Marked to Severe Anxiety Levels 75-80 Extreme Anxiety Levels

9. Anxiety as Assessed by the Zung Self-Rated Anxiety Scale [week 3]

   The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80: 20-44 Normal Range 45-59 Mild to Moderate Anxiety Levels 60-74 Marked to Severe Anxiety Levels 75-80 Extreme Anxiety Levels

10. Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C) [week 1]

    With the Visual Analogue Stress Scale - Current (VASS-C), current stress level is ranked on a 0 - 10 visual analog scale, with 0 as no stress and 10 as extreme stress, cued by the question "Please rate your current stress level."

11. Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C) [week 2]

    With the Visual Analogue Stress Scale - Current (VASS-C), current stress level is ranked on a 0 - 10 visual analog scale, with 0 as no stress and 10 as extreme stress, cued by the question "Please rate your current stress level."

12. Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C) [week 3]

    With the Visual Analogue Stress Scale - Current (VASS-C), current stress level is ranked on a 0 - 10 visual analog scale, with 0 as no stress and 10 as extreme stress, cued by the question "Please rate your current stress level."

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 45 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Marijuana substance use disorder based on a score of ≥ 13 on the Cannabis Use Disorders Identification Test - Revised (CUDIT-R)

• a score of ≥ 4 on the Cannabis Abuse Screening Test (CAST)

• meeting criteria for a marijuana substance use disorder based on the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV)

Exclusion Criteria:

• Current DSM-IV Axis I disorder other than marijuana use disorder

• serious medical illness requiring ongoing medical treatment, which could affect the central nervous system, or any other medical contraindication (e.g., renal, cardiovascular, pulmonary, blood) as determined by medical screening

• a positive pregnancy test or breast feeding (females)

• concomitant use of prescription medications that could affect the central nervous system

• active suicidal ideation or Beck Depression Inventory II score greater than 19

• positive urine drug screen for drugs other than marijuana or positive breath alcohol screen

• Shipley-2 test of cognitive aptitude score outside 2 SD units of the published composite score average

• smoking > 10 nicotine cigarettes per day / Fagerstrom Score > 4

• taking meds known to have significant drug interactions with buspirone.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Texas Health Science Center - Houston	Houston	Texas	United States	77030

Sponsors and Collaborators

• The University of Texas Health Science Center, Houston
• National Institute on Drug Abuse (NIDA)

Investigators

• Principal Investigator: Scott D. Lane, PhD, The University of Texas Health Science Center, Houston

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Scott Lane, Professor, The University of Texas Health Science Center, Houston
• ClinicalTrials.gov Identifier: NCT02132832
• Other Study ID Numbers: buspirone, stress, marijuana; R21DA034825
• First Posted: May 7, 2014
• Last Update Posted: Jun 2, 2017
• Last Verified: May 1, 2017

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No
• Keywords provided by Scott Lane, Professor, The University of Texas Health Science Center, Houston: marijuana; attentional bias; stress; buspirone
• Additional relevant MeSH terms: Marijuana Abuse; Buspirone

Study Results

Participant Flow

Pre-assignment Detail	45 were enrolled (i.e., screened and consented), but 3 participants never returned to begin the study. Thus, only 42 participants began the study.

Arm/Group Title	Buspirone	Placebo
Arm/Group Description	Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.	Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
Period Title: Overall Study
STARTED	19	23
COMPLETED	16	16
NOT COMPLETED	3	7

Baseline Characteristics

Arm/Group Title	Buspirone	Placebo	Total
Arm/Group Description	Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.	Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.	Total of all reporting groups
Overall Participants	19	23	42
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	29.16 (7.15)	29.52 (6.89)	29.34 (7.02)
Sex: Female, Male (Count of Participants)
Female	8 42.1%	10 43.5%	18 42.9%
Male	11 57.9%	13 56.5%	24 57.1%
Region of Enrollment (participants) [Number]
United States	19 100%	23 100%	42 100%

Outcome Measures

1. Primary Outcome

Title	Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements
Description	Eye movements are analyzed using a MiraMetrix S2 Eyetracker. This outcome measure reports a ratio: [(number of anti-saccade errors with marijuana-related images) divided by (total number of anti-saccade errors with marijuana-related images or neutral images)]. Anti-saccade errors are when the subject fails to inhibit fixation onto the image.
Time Frame	week 1

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Buspirone	Placebo
Arm/Group Description	Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.	Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
Measure Participants	16	16
Mean (Standard Deviation) [ratio of errors (see OM description)]	0.5795019 (0.1609511)	0.5539831 (0.1442601)

2. Primary Outcome

Title	Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements
Description	Eye movements are analyzed using a MiraMetrix S2 Eyetracker. This outcome measure reports a ratio: [(number of anti-saccade errors with marijuana-related images) divided by (total number of anti-saccade errors with marijuana-related images or neutral images)]. Anti-saccade errors are when the subject fails to inhibit fixation onto the image.
Time Frame	week 2

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Buspirone	Placebo
Arm/Group Description	Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.	Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
Measure Participants	16	16
Mean (Standard Deviation) [ratio of errors (see OM description)]	0.5517691 (0.1319968)	0.4979594 (0.1486691)

3. Primary Outcome

Title	Attentional Bias to Marijuana Specific Stimuli Measured Via Analysis of Eye Movements
Description	Eye movements are analyzed using a MiraMetrix S2 Eyetracker. This outcome measure reports a ratio: [(number of anti-saccade errors with marijuana-related images) divided by (total number of anti-saccade errors with marijuana-related images or neutral images)]. Anti-saccade errors are when the subject fails to inhibit fixation onto the image.
Time Frame	week 3

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Buspirone	Placebo
Arm/Group Description	Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.	Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
Measure Participants	16	16
Mean (Standard Deviation) [ratio of errors (see OM description)]	0.5503957 (0.1133407)	0.531073 (0.1991689)

4. Primary Outcome

Title	Stress as Assessed by the Perceived Stress Scale
Description	The Perceived Stress Scale is a 10 item scale that was developed to measure the degree to which individuals appraise their life as stressful and has been widely used in health studies. The scale has a 5-point Likert response format. The total score is calculated by summing responses. The questions are general in nature and relatively content free with regard to specific population groups. The range of scores is 0-40, with 40 indicating the most stress.
Time Frame	week 1

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Buspirone	Placebo
Arm/Group Description	Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.	Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
Measure Participants	16	16
Mean (Standard Deviation) [units on a scale]	15.05556 (5.885898)	18.57895 (6.551639)

5. Primary Outcome

Title	Stress as Assessed by the Perceived Stress Scale
Description	The Perceived Stress Scale is a 10 item scale that was developed to measure the degree to which individuals appraise their life as stressful and has been widely used in health studies. The scale has a 5-point Likert response format. The total score is calculated by summing responses. The questions are general in nature and relatively content free with regard to specific population groups. The range of scores is 0-40, with 40 indicating the most stress.
Time Frame	week 2

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Buspirone	Placebo
Arm/Group Description	Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.	Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
Measure Participants	16	16
Mean (Standard Deviation) [units on a scale]	13.88889 (6.434182)	16.42105 (5.708822)

6. Primary Outcome

Title	Stress as Assessed by the Perceived Stress Scale
Description	The Perceived Stress Scale is a 10 item scale that was developed to measure the degree to which individuals appraise their life as stressful and has been widely used in health studies. The scale has a 5-point Likert response format. The total score is calculated by summing responses. The questions are general in nature and relatively content free with regard to specific population groups. The range of scores is 0-40, with 40 indicating the most stress.
Time Frame	week 3

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Buspirone	Placebo
Arm/Group Description	Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.	Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
Measure Participants	16	16
Mean (Standard Deviation) [units on a scale]	10.38889 (6.436467)	14.05263 (7.799385)

7. Primary Outcome

Title	Anxiety as Assessed by the Zung Self-Rated Anxiety Scale
Description	The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80: 20-44 Normal Range 45-59 Mild to Moderate Anxiety Levels 60-74 Marked to Severe Anxiety Levels 75-80 Extreme Anxiety Levels
Time Frame	week 1

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Buspirone	Placebo
Arm/Group Description	Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.	Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
Measure Participants	16	16
Mean (Standard Deviation) [units on a scale]	32.44444 (2.955)	32.52632 (4.880442)

8. Primary Outcome

Title	Anxiety as Assessed by the Zung Self-Rated Anxiety Scale
Description	The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80: 20-44 Normal Range 45-59 Mild to Moderate Anxiety Levels 60-74 Marked to Severe Anxiety Levels 75-80 Extreme Anxiety Levels
Time Frame	week 2

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Buspirone	Placebo
Arm/Group Description	Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.	Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
Measure Participants	16	16
Mean (Standard Deviation) [units on a scale]	31.5 (3.714043)	31.57895 (3.79057)

9. Primary Outcome

Title	Anxiety as Assessed by the Zung Self-Rated Anxiety Scale
Description	The Zung Self-Rated Anxiety Scale is a widely-used 20 item scale that is scored on a Likert-type scale of 1-4, with 15 questions concerning increasing anxiety levels and five questions concerning decreasing anxiety levels. The scale focuses on the most common general anxiety symptoms and means of coping with stressors that produce anxiety. The range of scores is 20-80: 20-44 Normal Range 45-59 Mild to Moderate Anxiety Levels 60-74 Marked to Severe Anxiety Levels 75-80 Extreme Anxiety Levels
Time Frame	week 3

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Buspirone	Placebo
Arm/Group Description	Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.	Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
Measure Participants	16	16
Mean (Standard Deviation) [units on a scale]	33.27778 (4.884616)	31.63158 (4.125941)

10. Primary Outcome

Title	Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C)
Description	With the Visual Analogue Stress Scale - Current (VASS-C), current stress level is ranked on a 0 - 10 visual analog scale, with 0 as no stress and 10 as extreme stress, cued by the question "Please rate your current stress level."
Time Frame	week 1

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Buspirone	Placebo
Arm/Group Description	Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.	Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
Measure Participants	16	16
Mean (Standard Deviation) [units on a scale]	3.888889 (2.373602)	3.631579 (3.515213)

11. Primary Outcome

Title	Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C)
Description	With the Visual Analogue Stress Scale - Current (VASS-C), current stress level is ranked on a 0 - 10 visual analog scale, with 0 as no stress and 10 as extreme stress, cued by the question "Please rate your current stress level."
Time Frame	week 2

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Buspirone	Placebo
Arm/Group Description	Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.	Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
Measure Participants	16	16
Mean (Standard Deviation) [units on a scale]	3 (2.44949)	2.789474 (2.636895)

12. Primary Outcome

Title	Stress as Assessed by the Visual Analogue Stress Scale-Current (VASS-C)
Description	With the Visual Analogue Stress Scale - Current (VASS-C), current stress level is ranked on a 0 - 10 visual analog scale, with 0 as no stress and 10 as extreme stress, cued by the question "Please rate your current stress level."
Time Frame	week 3

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Buspirone	Placebo
Arm/Group Description	Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.	Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
Measure Participants	16	16
Mean (Standard Deviation) [units on a scale]	1.944444 (1.862074)	2.526316 (2.50263)

Adverse Events

Time Frame	3 weeks
Adverse Event Reporting Description	National Institute on Drug Abuse (NIDA) Serious Adverse Event Tracking and Reporting System (SAETRS); side effects profile
Arm/Group Title	Buspirone		Placebo
Arm/Group Description	Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.		Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
All Cause Mortality
	Buspirone		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)
Serious Adverse Events
	Buspirone		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/19 (0%)		0/23 (0%)
Other (Not Including Serious) Adverse Events
	Buspirone		Placebo
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	1/19 (5.3%)		0/23 (0%)
Nervous system disorders
light-headed, dizziness	1/19 (5.3%)	1	0/23 (0%)	0

Limitations/Caveats

The study intends to evaluate reduction of attentional-bias in non-treatment seekers, and it is not designed or powered to address treatment effects on marijuana use.

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.